Pharmaceutical Business Review
Return to: PBR Home

News

View news from other Pharmaceutical sectors:
106-120 of 51311 results
EMA approves Lynparza tablets to treat platinum-sensitive relapsed ovarian cancer
By PBR Staff Writer
AstraZeneca and Merck have secured approval from the European Medicines Agency (EMA) for Lynparza tablets to treat patients with platinum-sensitive relapsed ovarian cancer.
Regulatory Affairs > News
Medidata's Edge Trial Assurance uses AI to find clinical trial data quality issues
Medidata Solutions has unveiled Edge Trial Assurance service to transform how clinical trial data is validated prior to FDA submission.
News
FDA approves updated label of Relypsa’s Veltassa hyperkalemia drug
The US Food and Drug Administration (FDA) has approved Relypsa’ supplemental new drug application (sNDA) for Veltassa (patiromer) for oral suspension in the treatment of hyperkalemia, or elevated blood potassium levels.
News
Takeda agrees to acquire Shire for £45.3bn
By PBR Staff Writer
Takeda Pharmaceutical has agreed to acquire Ireland-based rare disease biotech company Shire in a cash-cum stock deal worth around £45.3bn.
Production & Manufacturing > Manufacturing > News
AstraZeneca to sell Seroquel drug rights to Luye Pharma for $538m
By PBR Staff Writer
AstraZeneca has agreed to sell the rights to its Seroquel schizophrenia treatment to China-based Luye Phara for $538m.
Drug Research > Drug Delivery > News
Lannett buys 23 generic drug products from Endo subsidiary
Lannett has acquired 23 approved and one pending drug product applications from a subsidiary of Endo International for an undisclosed amount along with future milestone payments.
Drug Research > Drug Delivery > News
Amneal, Impax form Amneal Pharmaceuticals
Amneal Pharmaceuticals and Impax Laboratories have completed their business combination to form Amneal Pharmaceuticals.
Drug Research > Drug Discovery & Development > News
Roche’s Tecentriq combo gets FDA priority review to treat lung cancer
By PBR Staff Writer
Roche’s cancer immunotherapy Tecentriq (atezolizumab) in combination with chemotherapy has been granted priority review in the US for the treatment of a specific type of metastatic lung cancer.
Production & Manufacturing > Process & Production > News
InDex Pharmaceuticals develops oral formulation of Cobitolimod
InDex Pharmaceuticals Holding has developed a novel formulation of its lead drug candidate cobitolimod for oral administration, with targeted delivery to the lower part of the gastrointestinal tract.
Drug Research > Drug Discovery & Development > News
Alkermes launches award program for research on CNS disorders
Alkermes has launched a new competitive awards program called the ALKERMES Pathways Research Awards Program to support the next generation of researchers working on the front lines to advance understanding and awareness of central nervous system (CNS) disorders.
Drug Research > Drug Discovery & Development > News
Novartis’ Tafinlar/Mekinist combo gets FDA nod for anaplastic thyroid cancer
By PBR Staff Writer
Novartis Pharmaceuticals has secured approval from the US Food and Drug Administration for its Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy to treat anaplastic thyroid cancer (ATC).
Regulatory Affairs > News
Horizon Discovery rejects £270m takeover proposal from Abcam
By PBR Staff Writer
UK-based Horizon Discovery Group has rejected a £270m offer from Abcam, saying that it is highly opportunistic and undervalues the company and its future prospects.
Drug Research > Drug Discovery & Development > News
monARC starts integration with Roivant's drug development platform
monARC Bionetworks has started an integration with the drug development platform of Roivant Sciences, a biopharmaceutical company focused on reducing the time and cost of the drug development process.
News
Casma Therapeutics raises $58.5m in Series A funding
Third Rock Ventures has launched Casma Therapeutics with a $58.5m investment to harness the cellular process of autophagy to develop breakthrough therapies.
Drug Research > Drug Discovery & Development > News
Merck to invest $125m in Moderna Therapeutics
By PBR Staff Writer
Merck has agreed to invest $125m in Moderna Therapeutics under a new agreement that expands the firms’ 2016 partnership to develop messenger RNA (mRNA) cancer vaccines.
Contract Research & Services > Clinical Trials > News
106-120 of 51311 results